Del Mar Reports Positive Phase II Data from China Trial of GBM Treatment

Del Mar Pharma of Vancouver and Menlo Park reported early results from its China Phase II trial of VAL-083 as a first line treatment for glioblastoma multiforme. VAL-083 is being administered along with radiation to patients with newly-diagnosed, MGMT-unmethylated GBM. Among the first 17 patients who have had three post-treatment examinations, 53% showed a complete response and 41% had stable disease. Only one of the 17 has died. The trial is being conducted in collaboration with Guangxi Wuzhou Pharma, Del Mar's China partner.More details.... Stock Symbol: (NSDQ: DMPI) Share this with colleagues: // //